Category - Developments

Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for...

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the...

YouScript, a clinical decision support tool designed to assist in medication therapy management, has been shown to reduce hospital readmissions by 52% and ER visits by 42% in patients over 50 taking multiple medications...

BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute. The technology was...

Avivagen (TSX-V:VIV), with the help of the National Research Council of Canada (NRC), will undertake a project to establish proof of concept for a first human health application of its OxC-beta technology. The project...

The Massachusetts Life Sciences Center (MLSC) has launched the Massachusetts Ramp-Up Program (MassRamp), a new program that will provide grant funding to promising early-stage life sciences companies. The program will...

A team of Stanford researchers trained a computer to identify images of skin cancer moles and lesions as accurately as a dermatologist, according to a new paper published in the journal, Nature. The new research...

The FDA has accepted for review Adamis Pharmaceuticals’ (NASDAQ:ADMP) NDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. Filed last Dec. 15, the resubmission...

Titan Pharmaceuticals’ (NASDAQ:TTNP) development and commercialization partner for Probuphine, closely held Braeburn Pharmaceuticals, announced that the Centers for Medicare & Medicaid Services (CMS) has granted a...